Literature DB >> 31125629

Association between cannabis laws and opioid prescriptions among privately insured adults in the US.

Mukaila A Raji1, N Ogechi Abara2, Habeeb Salameh3, Jordan R Westra4, Yong-Fang Kuo5.   

Abstract

We examine the association between opioid prescription patterns in privately insured adults and changes in state cannabis laws among five age groups (18-25, 26-35 36-45, 46-55 and 56-64 years). Using the 2016 Clinformatics Data Mart, a nationwide commercial health insurance database, we performed a cross-sectional analysis of two types of opioid prescribing (>30-day and >90-day prescriptions) among all adults aged 18-64 based on the stringency of cannabis laws. We found a significant interaction between age and cannabis law on opioid prescriptions. Age-stratified multilevel multivariable analyses showed lower opioid prescription rates in the four younger age groups only in states with medical cannabis laws, when considering both >30 day and >90 day opioid use [>30 day adjusted odds ratio (aOR) = 0.56, in 18-25, aOR = 0.67 in 26-35, aOR = 0.67 in 36-45, and aOR = 0.76 in 46-54 years; >90 day aOR = 0.56, in 18-25, aOR = 0.68 in 26-35, aOR = 0.69 in 36-45, and aOR = 0.77 in 46-54 years, P < 0.0001 for all]. This association was not significant in the oldest age group of 55-64 years. There was no significant association between opioid prescriptions and other categories of cannabis laws (recreational use and decriminalization) in any of the age groups studied.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabis; Commercial insurance; Cross-sectional; Marijuana; Medical cannabis; Opioid; Prescription

Year:  2019        PMID: 31125629      PMCID: PMC6582995          DOI: 10.1016/j.ypmed.2019.05.012

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  33 in total

1.  Should Physicians Recommend Replacing Opioids With Cannabis?

Authors:  Keith Humphreys; Richard Saitz
Journal:  JAMA       Date:  2019-02-19       Impact factor: 56.272

Review 2.  Marijuana Legalization: Impact on Physicians and Public Health.

Authors:  Samuel T Wilkinson; Stephanie Yarnell; Rajiv Radhakrishnan; Samuel A Ball; Deepak Cyril D'Souza
Journal:  Annu Rev Med       Date:  2015-10-19       Impact factor: 13.739

3.  Schedules of controlled substances: rescheduling of hydrocodone combination products from schedule III to schedule II. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2014-08-22

4.  National Estimates of Marijuana Use and Related Indicators - National Survey on Drug Use and Health, United States, 2002-2014.

Authors:  Alejandro Azofeifa; Margaret E Mattson; Gillian Schauer; Tim McAfee; Althea Grant; Rob Lyerla
Journal:  MMWR Surveill Summ       Date:  2016-09-02

5.  The Association Between Local Economic Conditions and Opioid Prescriptions Among Disabled Medicare Beneficiaries.

Authors:  Chao Zhou; Ning Neil Yu; Jan L Losby
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

6.  Why health care process performance measures can have different relationships to outcomes for patients and hospitals: understanding the ecological fallacy.

Authors:  John W Finney; Keith Humphreys; Daniel R Kivlahan; Alex H S Harris
Journal:  Am J Public Health       Date:  2011-07-21       Impact factor: 9.308

7.  Distribution of Prescription Opioid Use Among Privately Insured Adults Without Cancer: United States, 2001 to 2013.

Authors:  Eric C Sun; Anupam B Jena
Journal:  Ann Intern Med       Date:  2017-09-12       Impact factor: 25.391

8.  Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees.

Authors:  Hefei Wen; Jason M Hockenberry
Journal:  JAMA Intern Med       Date:  2018-05-01       Impact factor: 21.873

Review 9.  Emerging Evidence for Cannabis' Role in Opioid Use Disorder.

Authors:  Beth Wiese; Adrianne R Wilson-Poe
Journal:  Cannabis Cannabinoid Res       Date:  2018-09-01

10.  Association of Chronic Opioid Use With Presidential Voting Patterns in US Counties in 2016.

Authors:  James S Goodwin; Yong-Fang Kuo; David Brown; David Juurlink; Mukaila Raji
Journal:  JAMA Netw Open       Date:  2018-06-01
View more
  4 in total

1.  Association between fatal opioid overdose and state medical cannabis laws in US national survey data, 2000-2011.

Authors:  June H Kim; Silvia S Martins; Dvora Shmulewitz; Deborah Hasin
Journal:  Int J Drug Policy       Date:  2021-09-26

2.  Association of medical cannabis licensure with prescription opioid receipt: A population-based, individual-level retrospective cohort study.

Authors:  William C Goedel; Alexandria Macmadu; Abdullah Shihipar; Patience Moyo; Magdalena Cerdá; Brandon D L Marshall
Journal:  Int J Drug Policy       Date:  2021-10-23

3.  Mapping cannabis potency in medical and recreational programs in the United States.

Authors:  Mary Catherine Cash; Katharine Cunnane; Chuyin Fan; E Alfonso Romero-Sandoval
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

4.  Protocol: mixed-methods study of how implementation of US state medical cannabis laws affects treatment of chronic non-cancer pain and adverse opioid outcomes.

Authors:  Emma E McGinty; Kayla N Tormohlen; Colleen L Barry; Mark C Bicket; Lainie Rutkow; Elizabeth A Stuart
Journal:  Implement Sci       Date:  2021-01-07       Impact factor: 7.327

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.